Patents by Inventor Richard Lewanczuk

Richard Lewanczuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080200414
    Abstract: Novel nucleic acids and corresponding encoded proteins are described. Also described are corresponding recombinant vectors and host cells, as well as methods of producing the proteins. Also described are mimetics and antibodies to the proteins as well as compositions comprising the nucleic acid or proteins or a portion thereof. Methods and kits for the detection of a disease, disorder or abnormal physical state caused by abnormal modulation of calcium levels in a patient are also described. Methods for treating a patient having a disease, disorder or abnormal physical state caused by abnormal calcium levels are also described. Methods for assaying abnormal calcium levels are also described, as are methods for screening the efficacy of products for modulating abnormal calcium levels.
    Type: Application
    Filed: November 13, 2007
    Publication date: August 21, 2008
    Applicant: Centre de Recherche du CHUM
    Inventors: Johanne Tremblay, Pavel Hamet, Richard Lewanczuk, Francis Gossard, Nicolas Solban
  • Patent number: 7118919
    Abstract: Use of 13C glucose in an analytical assay to monitor glucose metabolism by measurement of labeled exhaled CO2 is provided. A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: October 10, 2006
    Assignee: Isotechnika Inc.
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Publication number: 20050181442
    Abstract: This invention relates to a novel gene that shows tissue specific expression and increased expression in a low calcium concentration medium. Low renin hypertension is characterized by decreased levels of serum ionized calcium in the presence of increased levels of parathyroid hormone. It is hypothesized that hypertensive factor(s) are co-secreted with PTH in SHR, a model of low renin hypertension, the parathyroid hypertensive factor being one of them. As a negative calcium balance is present in spontaneously hypertensive rats (SHR), we searched for gene(s) involved in this dysregulation. A cDNA library was constructed from the SHR parathyroid gland which is a key regulator of serum ionized calcium. From 7 overlapping DNA fragments, a 1100-bp novel cDNA containing an open reading frame of 224 codons was reconstituted.
    Type: Application
    Filed: April 19, 2005
    Publication date: August 18, 2005
    Applicant: Centre de Recherche du CHUM
    Inventors: Johanne Tremblay, Pavel Hamet, Richard Lewanczuk, Francis Gossard, Nicolas Solban
  • Publication number: 20050147560
    Abstract: Use of 13C glucose in an analytical assay to monitor glucose metabolism by measurement of labeled exhaled CO2 is provided. A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Application
    Filed: February 28, 2005
    Publication date: July 7, 2005
    Applicant: Isotechnika Inc.
    Inventors: Randall Yatscoff, Robert Foster, Launa Aspeslet, Richard Lewanczuk
  • Patent number: 6878550
    Abstract: Use of 13C glucose in an analytical assay to monitor glucose metabolism by measurement of labeled exhaled CO2 is provided. A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: April 12, 2005
    Assignee: Isotechnika Inc.
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Publication number: 20040253180
    Abstract: A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
    Type: Application
    Filed: March 5, 2004
    Publication date: December 16, 2004
    Inventors: Robert T. Foster, Richard Lewanczuk, Gilles Caille
  • Patent number: 6818200
    Abstract: A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: November 16, 2004
    Assignee: Isotechnika Inc.
    Inventors: Robert T. Foster, Richard Lewanczuk, Gilles Caille
  • Publication number: 20040038412
    Abstract: Use of 13C glucose in an analytical assay to monitor glucose metabolism by measurement of labeled exhaled CO2 is provided. A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Application
    Filed: May 16, 2003
    Publication date: February 26, 2004
    Applicant: Isotechnika Inc.
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Patent number: 6602715
    Abstract: A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: August 5, 2003
    Assignee: Isotechnika Inc.
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Patent number: 6599750
    Abstract: Use of 13C glucose in an analytical assay to monitor glucose metabolism by measurement of labeled exhaled CO2 is provided. A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: July 29, 2003
    Assignee: Isotechnika Inc.
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Publication number: 20030049853
    Abstract: Use of 13C glucose in an analytical assay to monitor glucose metabolism by measurement of labeled exhaled CO2 is provided. A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Application
    Filed: August 27, 2002
    Publication date: March 13, 2003
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Publication number: 20030044993
    Abstract: A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Application
    Filed: August 27, 2002
    Publication date: March 6, 2003
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Patent number: 6468802
    Abstract: A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: October 22, 2002
    Assignee: Isotechnika, Inc.
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Patent number: 6461870
    Abstract: Use of 13C glucose in an analytical assay to monitor glucose metabolism by measurement of labeled exhaled CO2 is provided. A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: October 8, 2002
    Assignee: Isotechnika Inc.
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Publication number: 20020115604
    Abstract: This invention relates to a novel gene that shows tissue specific expression and increased expression in a low calcium concentration medium. Low renin hypertension is characterized by decreased levels of serum ionized calcium in the presence of increased levels of parathyroid hormone. It is hypothesized that hypertensive factor(s) are co-secreted with PTH in SHR, a model of low renin hypertension, the parathyroid hypertensive factor being one of them. As a negative calcium balance is present in spontaneously hypertensive rats (SHR), we searched for gene(s) involved in this dysregulation. A cDNA library was constructed from the SHR parathyroid gland which is a key regulator of serum ionized calcium. From 7 overlapping DNA fragments, a 1100-bp novel cDNA containing an open reading frame of 224 codons was reconstituted.
    Type: Application
    Filed: July 16, 2001
    Publication date: August 22, 2002
    Inventors: Johanne Tremblay, Pavel Hamet, Richard Lewanczuk, Francis Grossard, Nicolas Solban
  • Publication number: 20020094995
    Abstract: A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
    Type: Application
    Filed: November 14, 2001
    Publication date: July 18, 2002
    Inventors: Robert T. Foster, Richard Lewanczuk, Gilles Caille
  • Publication number: 20020042143
    Abstract: Use of 13C glucose in an analytical assay to monitor glucose metabolism by measurement of labeled exhaled CO2 is provided. A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.
    Type: Application
    Filed: July 20, 2001
    Publication date: April 11, 2002
    Inventors: Randall W. Yatscoff, Robert T. Foster, Launa J. Aspeslet, Richard Lewanczuk
  • Patent number: 6334997
    Abstract: A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: January 1, 2002
    Assignee: Isotechnika, Inc.
    Inventors: Robert T. Foster, Richard Lewanczuk, Gilles Caille
  • Patent number: 5846514
    Abstract: A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: December 8, 1998
    Assignee: Isotechnika, Inc.
    Inventors: Robert T. Foster, Richard Lewanczuk, Gilles Caille